tiprankstipranks
Trending News
More News >
Zimmer Biomet Holdings (ZBH)
NYSE:ZBH
US Market

Zimmer Biomet Holdings (ZBH) Earnings Dates, Call Summary & Reports

Compare
1,097 Followers

Earnings Data

Report Date
May 05, 2026
Before Open (Confirmed)
Period Ending
2026 (Q1)
Consensus EPS Forecast
1.86
Last Year’s EPS
1.81
Same Quarter Last Year
Based on 20 Analysts Ratings

Earnings Call Summary

Q4 2025
Earnings Call Date:Feb 10, 2026|
% Change Since:
|
Earnings Call Sentiment|Neutral
The call balanced encouraging operational and product momentum (notably product adoption in hips/knees, robotics strength, robust free cash flow generation, and a sizable buyback program) with significant near-term execution risks (a large U.S. salesforce transformation, pricing/gross margin pressure, higher interest expense and fragile international pockets). Management provided concrete guidance (1%–3% revenue growth and $8.30–$8.45 adjusted EPS for 2026) and emphasized long-term upside from innovation and channel changes while acknowledging short-term disruption.
Company Guidance
Zimmer Biomet guided 2026 to organic constant‑currency revenue growth of 1%–3% (growth roughly consistent quarter‑to‑quarter), adjusted EPS of $8.30–$8.45, and free cash flow growth of 8%–10% (with free cash flow conversion approaching ~80%); the outlook includes a ~100‑bp contribution from Paragon 28 to reported sales before it enters organic in April, an expected FX tailwind of ~50 bps to full‑year revenue (about +250 bps in Q1), up to 100 bps of pricing erosion, and assumes end‑market growth in line with 2025 while allowing for disruption from the U.S. salesforce transition and international go‑to‑market evolution. They expect full‑year operating margins to be down roughly 50 bps from 2025 (Q1 down ~100 bps yoy, then improving ~100 bps into Q2), adjusted net interest and other non‑operating expenses of ~ $295 million, an adjusted effective tax rate of ~18%, and diluted shares of about 194–195 million (reflecting a 2026 buyback program of up to $750 million; the board has authorized up to $1.5 billion of repurchases overall).
Solid Q4 and FY25 Organic Revenue Growth
Q4 organic constant-currency sales grew 5.4% (consolidated); U.S. organic growth 5.7% and International organic growth 5.0%. Full-year 2025 organic constant-currency sales grew 3.9%.
Strong Product Adoption in Joints
U.S. knee revenue +6% in Q4 with Persona OsteoTide ~35% penetration and high adoption of Oxford partial cementless knee; U.S. hip revenue nearly +8% in Q4 with implant C1 representing >35% of U.S. hip stems.
Robotics, Technology and Capital Sales Momentum
U.S. technology/data/bone cement/surgical cells increased >10% in Q4, driven by the strongest robotic capital sales quarter in over two years; continued expansion of robotics/navigation offerings including MBOS (Monogram).
Healthy Cash Generation and Free Cash Flow
Q4 operating cash flow $517M and Q4 free cash flow $368M; full-year 2025 free cash flow $1.172B, up >11% year-over-year; company expects free cash flow growth of 8%–10% in 2026 and ~80% FCF conversion.
Adjusted EPS Growth and Share Count Reduction
Q4 adjusted diluted EPS $2.42, up 4.8% year-over-year; full-year adjusted EPS $8.20. Fully diluted shares were 198.1M (down YoY), aided by share repurchases of $250M in Q4.
Capital Return and Balance Sheet Actions
Board approved buyback authority and activity: $250M repurchased in Q4 2025, board authorization up to $1.5B, and management disclosed share buybacks in 2026 of up to $750M; cash & cash equivalents ~ $592M at year-end.
Robust Innovation and Portfolio Progress
Management highlighted closed core portfolio gaps, the 'magnificent seven' platform, iodine-coated devices (Japan launch), Oxford partial cementless knee, and Monogram/MBOS—pipeline ~3x what it was a few years ago with multiple launches planned in 2026.
Progress on U.S. Go-to-Market Changes
Company has completed ~one-third of the transition to a dedicated/specialized U.S. sales channel; plans to complete majority conversion by end of 2027 and to add specialized reps (e.g., 200+ robotics reps) to target higher growth areas like SCT and ASCs.

Zimmer Biomet Holdings (ZBH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

ZBH Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
May 05, 2026
2026 (Q1)
1.86 / -
1.81
Feb 10, 2026
2025 (Q4)
2.40 / 2.42
2.314.76% (+0.11)
Nov 05, 2025
2025 (Q3)
1.87 / 1.90
1.749.20% (+0.16)
Aug 07, 2025
2025 (Q2)
1.98 / 2.07
2.012.99% (+0.06)
May 05, 2025
2025 (Q1)
1.77 / 1.81
1.94-6.70% (-0.13)
Feb 06, 2025
2024 (Q4)
2.29 / 2.31
2.25.00% (+0.11)
Oct 30, 2024
2024 (Q3)
1.74 / 1.74
1.655.45% (+0.09)
Aug 07, 2024
2024 (Q2)
1.99 / 2.01
1.8210.44% (+0.19)
May 02, 2024
2024 (Q1)
1.87 / 1.94
1.892.65% (+0.05)
Feb 08, 2024
2023 (Q4)
2.15 / 2.20
1.8817.02% (+0.32)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

ZBH Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 10, 2026
$89.73$91.40+1.86%
Nov 05, 2025
$102.91$87.32-15.15%
Aug 07, 2025
$90.69$97.93+7.99%
May 05, 2025
$101.59$89.79-11.62%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Zimmer Biomet Holdings (ZBH) report earnings?
Zimmer Biomet Holdings (ZBH) is schdueled to report earning on May 05, 2026, Before Open (Confirmed).
    What is Zimmer Biomet Holdings (ZBH) earnings time?
    Zimmer Biomet Holdings (ZBH) earnings time is at May 05, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ZBH EPS forecast?
          ZBH EPS forecast for the fiscal quarter 2026 (Q1) is 1.86.